[1] Association A. 2016 Alzheimer's disease facts and figures. Alzheimers Dement, 2016; 12, 459−509. doi:  10.1016/j.jalz.2016.03.001
[2] Hodson R. Alzheimer's disease. Nature, 2018; 559, S1. doi:  10.1038/d41586-018-05717-6
[3] Yeh FL, Hansen DV, Sheng M. TREM2, microglia, and neurodegenerative diseases. Trends Mol Med, 2017; 23, 512−33. doi:  10.1016/j.molmed.2017.03.008
[4] Sims R, van der Lee SJ, Naj AC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet, 2017; 49, 1373−84. doi:  10.1038/ng.3916
[5] Suárez-Calvet M, Kleinberger G, Caballero MÁA, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer’s disease and associate with neuronal injury markers. Embo Mol Med, 2016; 8, 466−76. doi:  10.15252/emmm.201506123
[6] Lee SH, Meilandt WJ, Xie LK, et al. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology. Neuron, 2021; 109, 1283−1301. e6. doi:  10.1016/j.neuron.2021.02.010
[7] Yu NH, Huang YP, Jiang Y, et al. Ganoderma lucidum triterpenoids (GLTs) reduce neuronal apoptosis via inhibition of ROCK signal pathway in APP/PS1 transgenic Alzheimer's disease mice. Oxid Med Cell Longev, 2020; 2020, 9894037.
[8] Chen LZ, Xu SC, Wu T, et al. Studies on APP metabolism related to age-associated mitochondrial dysfunction in APP/PS1 transgenic mice. Aging (Albany NY), 2019; 11, 10242−51.
[9] Ruan Z, Pathak D, Kalavai SV, et al. Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain, 2021; 144, 288−309. doi:  10.1093/brain/awaa376
[10] Schindler SE, Li Y, Todd KW, et al. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer’s disease. Alzheimers Dement, 2019; 15, 655−65. doi:  10.1016/j.jalz.2018.12.019